http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_990d93baa910ea000185456b8d8b56a7
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Katayama |
| name | Ryohei Katayama |
| given-name | Ryohei |
| organization-name | Massachusetts General Hospital Cancer Center, Boston, MA 02129;; Department of Medicine, Harvard Medical School, Boston, MA 02115; Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan Institute of Molecular and Cellular Biosciences 1Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts.; 2Department of Medicine, Harvard Medical School, Boston, Massachusetts.; 3Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan. 1The Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan. Division of Experimental Chemotherapy, Cancer Chemotherapy Center Japanese Foundation for Cancer Research Tokyo 135‐8550 Japan From the Massachusetts General Hospital Cancer Center; Harvard Medical School; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston; Infinity Pharmaceuticals, Inc, Cambridge, MA; Yale University School of Medicine and Yale Cancer Center, New Haven, CT; Mary Crowley Cancer Research Center, Dallas, TX; University of Washington, Seattle, WA; Mt Sinai Cancer Center, Miami Beach; Moffitt Cancer Center, Tampa, FL; and Cedars-Sinai Medical Center, Los Angeles, CA. Authors' Affiliations: 1Massachusetts General Hospital Cancer Center; 2Department of Medicine, Harvard Medical School, Boston, Massachusetts; 3Genomics Institute of the Novartis Research Foundation, San Diego, California; 4Cancer Chemotherapy Center and 5Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; Authors' Affiliations: 1Massachusetts General Hospital Cancer Center; 2Department of Medicine, Harvard Medical School, Boston, Massachusetts; 3Genomics Institute of the Novartis Research Foundation, San Diego, California; 4Cancer Chemotherapy Center and 5Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; Authors' Affiliations: 1Massachusetts General Hospital Cancer Center; 2Department of Medicine, Harvard Medical School, Boston, Massachusetts; 3Genomics Institute of the Novartis Research Foundation, San Diego, California; 4Cancer Chemotherapy Center and 5Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan Massachusetts General Hospital Cancer Center, Department of Medicine and Harvard Medical School, Boston, MA 02114, USA. 1Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan. Author affiliations appear at the end of this article. Authors' Affiliations: Departments of 1Medicine and 2Pathology, Massachusetts General Hospital, Boston, Massachusetts; Departments of 3Medicine and 4Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York; and 5Department of Medicine, University of California, Irvine, Orange, California 4Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan. Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan; Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA.; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA. Institute of Molecular and Cellular Biosciences, The University of Tokyo, Bunkyo-ku, Tokyo 113-0032, Japan; Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Koto-ku, Tokyo 135-8550, Japan 1Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts.; 4Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan. 1Cancer Chemotherapy Center, Japanese Foundation for Cancer Research; 1Cancer Chemotherapy Center, Japanese Foundation for Cancer Research and Division of Experimental Chemotherapy, The Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan 1Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan. Authors' Affiliations: 1Massachusetts General Hospital Cancer Center; 2Department of Medicine, Harvard Medical School, Boston, Massachusetts; Divisions of 3Experimental Chemotherapy and 4Molecular Pharmacology, Cancer Chemotherapy Center, Japanese foundation for Cancer Research; 5Department of Medical Genome Sciences, Graduate School of Frontier Sciences, The University of Tokyo; and 6Pharmaceuticals and Medical Devices Agency (PMDA), Tokyo, Japan; Authors' Affiliations: 1Massachusetts General Hospital Cancer Center; 2Department of Medicine, Harvard Medical School, Boston, Massachusetts; Divisions of 3Experimental Chemotherapy and 4Molecular Pharmacology, Cancer Chemotherapy Center, Japanese foundation for Cancer Research; 5Department of Medical Genome Sciences, Graduate School of Frontier Sciences, The University of Tokyo; and 6Pharmaceuticals and Medical Devices Agency (PMDA), Tokyo, Japan; Authors' Affiliations: 1Massachusetts General Hospital Cancer Center; 2Department of Medicine, Harvard Medical School, Boston, Massachusetts; Divisions of 3Experimental Chemotherapy and 4Molecular Pharmacology, Cancer Chemotherapy Center, Japanese foundation for Cancer Research; 5Department of Medical Genome Sciences, Graduate School of Frontier Sciences, The University of Tokyo; and 6Pharmaceuticals and Medical Devices Agency (PMDA), Tokyo, Japan |
Incoming Links
Total number of triples: 72.